Communiqués Atossa Therapeutics, Inc.

Actions

ATOS

US04962H7044

Recherche biotechnologique et médicale

Temps Différé Nasdaq 17:13:33 18/09/2026			Varia. 5j.	Varia. 1 janv.
2,364 ^USD	-1,52 %		-5,83 %	-73,29 %

07/08	Atossa Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/07	Atossa Therapeutics annonce la publication de nouveaux composés dérivés du (Z)-endoxifène démontrant une activité anticancéreuse puissante dans le cancer du sein ER-positif	CI

Communiqués

12/06	Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds	PR
20/05	Atossa Therapeutics : Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy	PU
04/05	Karolinska Institutet: New treatment with fewer side effects reduces breast density	AQ
11/02	Atossa Therapeutics : Investor Presentation (image/ATOS IR Deck 11 FEB FINAL web version)	PU
16/01	Atossa Therapeutics : Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy	PU
09/01	Atossa Therapeutics : Investor Presentation (image/ATOS Investor Relations Deck 9 JAN 26)	PU
22/10/25	Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference, Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents	AQ
18/10/25	Atossa Therapeutics : Investor Presentation (image/ATOS Deck Revised 80 20 Hierarchy 10 17 25)	PU
16/10/25	Atossa Therapeutics to Present at the Maxim Growth Summit 2025	AQ
26/09/25	Atossa Therapeutics : Investor Presentation (image/ATOS Deck Revised 80 20 Hierarchy Sept2025 FINAL FINAL)	PU
17/09/25	Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services	AQ
16/09/25	Atossa Therapeutics : Investor Presentation (image/ATOS Corporate Deck Revised Sept 16 2025)	PU
28/08/25	Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference	PR
20/08/25	Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer	PR
12/08/25	Atossa Therapeutics : Investor Presentation (image/ATOS Corporate Deck Revised AUG 2025 %28REDCHIP CFG v7%29%5B2%5D Read Only)	PU
12/08/25	Atossa Therapeutics : Investor Presentation (imageATOS Corporate Deck Revised AUG 2025 %28REDCHIP CFG v7%29%5B2%5D Read Only)	PU
12/08/25	Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update	PR
29/07/25	Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer	PR
02/06/25	Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference	PR
14/05/25	Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen	PR
13/05/25	Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update	PR
30/04/25	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio	AQ
29/04/25	Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025	AQ
22/04/25	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio	AQ
10/04/25	Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer	PR